MDMA and Basic Research References

MDMA and Basic Research:
Issues Within and Beyond Therapeutic Applications
MAPS Bulletin Vol 15 n 1 pp. 7-13

Lisa Jerome PhD

References

Adamson S (1985) Through the gateway of the heart: Accounts of experiences With MDMA and other empathogenic substances. Four Trees Publications, San Francisco, CA.
Aghajanian GK, Lieberman JA (2001) Caveat emptor: Editors Beware-Response. Neuropsychopharmacology, 24: 335-336.
Anderson, GM, Braun G, Braun, U, Nichols, DE, Shulgin, AT (1978) Absolute configuration and psychotomimetic activity. NIDA Research Monograph, 22: 8-15.
Aron A, Melinat E, Aron EN, Vallone RD, Bator RJ (1997) The experimental generation of interpersonal closeness; A procedure and some preliminary findings. Personality and Social Psychology Review, 23: 363-377.
Aronson E, Ellsworth PC, Carlsmith JM, Gonzales MH (1990) Methods of Research in Social Psychology (2nd Edition). New York: McGraw-Hill.
Baggott M, Jerome L, Stuart R (2001) 3,4-methylenedioxymethamphetamine (MDMA): A review of the English-language scientific and medical literature. On-line, http://www.maps.org/research/mdma/protocol/litreview.html..
Batson CD, Moran T (1999) Empathy-induced altruism in a prisoner's dilemma. European Journal of Social Psychology, 29: 909-924.
Batson CD, Ahmad N, Yin J, Bedell SJ, Johnson JW, Templin CM, Whiteside A (1999) Two threats to the common good; Self interested egoism and empathy and empathy-induced altruism. Personality and Social Psychology Bulletin, 25: 3-16.
Batson CD, Polycarpou MP, Harmon-Jones E, Imhoff H. et al. (1997). Empathy and attitudes: Can feeling for a member of a stigmatized group improve feelings toward the group. Journal of Personality and Social Psychology, 72: 105-118.
Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M. (2004) A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. American Journal of Psychiatry, 161:1181-1189.
Cacioppo JT (1994) Social neuroscience: Autonomic, neuroendocrine, and immune responses to stress Psychophysiology, 31: 113-128.
Cacioppo JT, Berntson GG, Crites SL (1996) Social neuroscience: Principles of psychological arousal and response. In Higgins, ET & Kruglanski, AK (Eds). Social Psychology: Handbook of Basic Principles (pp. 72-101). New York, NY: Guilford Press.
Cami J, Farre M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. Journal of Clinical Psychopharmacology, 20: 455-466.
Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, Poland, RE (2000) Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study. Psychiatry Research, 98: 15-28.
Clark MS, Reis HT (1988) Interpersonal processes in close relationships. In Rosensweig, M. R. & Porter, L. W. (Eds). Annual Review of Psychology, Vol. 39: pp. 607-672.
Clemens KJ, Van Nieuwenhuyzen PS, Li KM, Cornish JL, Hunt GE, McGregor IS. (2003) MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology (Berl), 173:318-325.
Cole JC, Sumnall HR (2003a) Altered states: the clinical effects of Ecstasy. Pharmacology and Therapeutics, 98:35-58.
Croft RJ, Mackay AJ, Mills ATD, Gruzelier, JGH (2001) The relative contribution of ecstasy and cannabis to cognitive impairment. Psychopharmacology, 153: 373-379.
Damasio A (1999) The Feeling of What Happens: Body and Emotion in the Making of Consciousness New York, NY: Harcourt.
Davison D, Parrott, AC, (1997) Ecstasy (MDMA) in recreational users: Self- reported psychological and physiological effects. Human Psychopharmacology, Clinical & Experimental, 12: 221-226.
Doblin R. (2000). Research updates. MAPS Bulletin, 10(2), 2
Doblin R. (2002) Letter from Rick Doblin, MAPS President. MAPS Bulletin, 12(3), 3
d'Otalora M (2001) MDMA and LSD Therapy in the Treatment of Post Traumatic Stress Disorder in a Case of Sexual Abuse http://www.maps.org/research/mdma/moaccount.html
Downing, J (1986) The psychological and physiological effects of MDMA on normal volunteers. Journal of Psychoactive Drugs, 18: 335-340.
Duan C, Hill, C (1996) The current state of empathy research. Journal of Counseling Psychology, 43: 261-274.
Farre M, De La Torre R, O Mathuna B, Roset PN, Peiro AM, Torrens M, Ortuno J, Pujadas M, Cami J (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl), 173 :3 64-375.
Fiske AP, Fairbanks L, Jentsch D, Salameh W, Jacoboni M, Jorgensen M (2004) Making connections: MDMA research on the mechanisms of affiliation and trust. Published on-line: http://www.sscnet.ucla.edu/anthro/faculty/fiske/research/MDMA_social_conection.htm.
Fiske S, Taylor, S (1991) Social Cognition. New York, NY: McGraw-Hill.
Fornai F, Lazzeri G, Lenzi P, Gesi M, Ferrucci M, Soldani P, Pellegrini A, Capobianco L, De Blasi A, Ruggieri S, Paparelli A. (2003) Amphetamines induce ubiquitin-positive inclusions within striatal cells. Neurological Sciences, 24: 182-183.
Forsling M, Fallon JA, Kicman AT, Hutt AJ, Cowan DA, Henry, JA (2001). Arginine vasopressin release in response to the administration of 3,4- methylenedioxymethamphetamine ("ecstasy"): is metabolism a contributory factor? Journal of Pharmacy and Pharmacology, 53: 1357-1363.
Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX (2000) 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacology, 23: 388-395.
Gamma A (2000) Does ecstasy cause memory deficits? A review of studies of memory function in ecstasy users. On-line http://www.maps.org/research/mdma/mdmamemory.html
Gasser P (1994) Psycholytic Therapy with MDMA and LSD in Switzerland. MAPS Newsletter 5: 3-7, http://www.maps.org/news-letters/v05n3/05303psy.html
Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R, Caccavari R, Delsignore, R (1998) Serotonin function after (+ / -) 3,4-methylenedioxymethamphetamine ("ecstasy") in humans. International Clinical Psychopharmacology, 13: 1-9.
Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, Marzocchi G F, Delsignore R, Brambilla, F (2000) Long-lasting effects of 3,4-methylenedioxymethamphetamine (Ecstasy) on serotonin system function in humans. Biological Psychiatry, 47: 127-136.
Gijsman HJ, Van Gerven JM, Verkes RJ, Schoemaker RC, Pieters MS, Pennings EJ, Hessing TJ,
Cohen AF (2002) Saccadic peak velocity and EEG as end-points for a serotonergic challenge test. Human Psychopharmacology. 17: 83-89.
Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar K-A,
Hermle L, Bull U, Sass H (1999) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers: A double blind, placebo-controlled PET study with [18F]FDF. Neuropsychopharmacology, 20: 565-581.
Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar K-A, Lindenblatt H, Hermle L, Spitzer M, Sass H (1999b) Psychopathological, neuroendocrine and autonomic effects of 3,4- methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo- controlled study. Psychopharmacology (Berl) 142: 41-50.
Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert H -J, Fimm B, Sass, H (2000) Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). Journal of Neurology, Neurosurgery and Psychiatry, 68: 719-725.
Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hansen G, Daumann J (2003) Memory impairments suggest hippocampal dysfunction in abstinent Ecstasy users. Progress in Neuropsychopharmacology and Biological Psychiatry, 27: 819-827.
Greer GR, Tolbert, RA (1998) A method of conducting therapeutic sessions with MDMA. Journal of Psychoactive Drugs, 30: 371-379.
Greer GR, Tolbert RA (1986) Subjective reports of the effects of MDMA in a clinical setting. Journal of Psychoactive Drugs, 18: 319-327.
Grob C Poland R, Chang L, Ernst T (1996) Psychobiological effects of 3,4-methylenedioxy- methamphetamine (MDMA): Methodological considerations and preliminary observations. Brain Behavioral Research, 73: 103-107.
Halpern JH, Pope HG, Sherwood AR, Barry S, Hudson JH, Yurgelun-Todd D (2004) Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug and Alcohol Dependence, 75: 135-147
Harris DS, Baggott M, Mendelson J, Mendelson JE, Jones RT (2002) Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl), 162: 396-405.
Hernandez-Lopez C, Farre M, Roset PN, Menoyo E, Pizarro N, Ortuno J, Torrens M, Cami J, de La Torre R (2002) 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. Journal ofPharmacology and Experimental Therapeutics, 300: 236-244.
Hoshi R, Bisla J, Curran HV, (2004) The acute and sub-acute effects of 'ecstasy' (MDMA) on processing of facial expressions: preliminary findings. Drug and Alcohol Dependence,76: 297-304 I
ckes W Stinson L, Bissonnette V, Garcia S (1991) Naturalistic social cognition: Empathic accuracy in mixed-sex dyads. Journal of Personality and Social Psychology, 59: 730-742.
Ickes W, Bissonnette V, Garcia S, Stinson LL (1990) Implementing and using the dyadic interaction paradigm. In Hendrick, C & Clark, MS (Eds). Research Methods in Personality and Social Psychology: Review of Personality and Social Psychology, 11. (Newbury Park, CA: Sage Publications) pp. 16-44.
Justice AH, DeWit, H (1999) Acute effects of d-amphetamine during the follicular and luteal phases of the menstrual cycle in women. Psychopharmacology, 145: 67-75.
Lamers CTJ, Ramaekers JG, Muntjewerff ND, Sikkema KL, Samyn N, Read NL, Brookhuis KA, Riedel WJ (2003) Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. Journal of Psychopharmacology, 17: 379-387.
LeDoux J (1998) The Emotional Brain: The mysterious underpinnings of emotional life. (London; Weidenfeld & Nicolson).
Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, Mendelson J (2000) Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Annals of Internal Medicine, 133: 969-973.
Levenson RW, Ruef, AM (1992) Empathy: A physiological substrate. Journal of Personality and Social Psychology, 63: 234-246.
Lieberman JA, Aghajanian GK (1999) Caveat emptor: researcher beware. Neuropsychopharmacology, 21: 471-473.
Liester MB, Grob CS, Bravo GL, Walsh, RN (1992) Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. Journal of Nervous and Mental Disease, 180: 345-352.
Liechti ME, Gamma A, Vollenweider, FX (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology, 154: 61-68.
Ludewig S, Ludewig K, Hasler F, Vollenweider FX (2003) No lasting effects of moderate doses of MDMA (Ecstasy) on memory performance and mood states in health humans. Biological Psychiatry. 53 (Suppl); 205S. Data presented at the 58th Annual Conference of the Society for Biological Psychiatry, San Francisco, CA.
Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. Journal of Pharmacology and Experimental Therapeutics, 290: 136-145.
Macrae CN, Milne, B (1992) A curry for your thoughts; Empathic effects on counterfactual thinking. Personality and Social Psychology Bulletin, 18: 625-630.
McCann U, Mertl M, Eligulashvili V, Ricaurte, GA (1999) Cognitive performance in 3,4-methylenedioxymethamphetamine (MDMA) users: A controlled study. Psychopharmacology, 143: 417-425.
Miller DB, O'Callaghan JP (1996) Neurotoxicity of d-amphetamine in the C57BL/6J and CD-1 mouse. Interactions with stress and the adrenal system. Annals of the New York Acadamy of Sciences, 801:148-167.
Mithoefer M, Wagner M (2001). A human phase II study: Safety and efficacy of 3,4-methylenedioxymethamphetamine (MDMA) assisted psychotherapy in the treatment of chronic posttraumatic stress disorder (PTSD). On-line: http://www.maps.org/research/mdma/protocol
Mithoefer M (2004c) MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder; a fourth update on the approval process and first report on study progress. MAPS Bulletin, 14(1): 3-4. http://www.maps.org/news-letters/v14n1-html/mdma_for_ptsd.html
Morgan, MJ (1999) Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacology, 141: 30-36.
Mortimore C, Anderson, IM (2000) D-Fenfluramine in panic disorder: A dual role for 5-hydroxytryptamine. Psychopharmacology, 149: 251-258.
Nash JF Jr., Meltzer HY, Gudelsky GA (1988) Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. Journal of Pharmacology and Experimental Therapeutics, 245: 873-879.
Nichols DE (1986) Differences between the mechanisms of action of MDMA, MBDB and the classic hallucinogenic drugs; Identification of a new therapeutic class, entactogens. Journal of Psychoactive Drugs, 18: 305-313.
Nichols DE, Oberlender, R (1990) Structure-activity relationships of MDMA and related compounds: A new class of psychoactive agents? In SJ Peroutka (Ed.), Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA.. Norwell MA; Kluwer Academic Publishers.
Oberlender R, Nichols DE (1988) Drug discrimination studies with MDMA and amphetamine. Psychopharmacology, 95: 71-76.
Pacifici R, Zuccaro P, Lopez CH, Pichini S, Di Carlo S, Farre M, Roset PN, Ortuno J, Segura J, Torre RL (2001) Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J Pharmacol Exp Ther 296: 207-215.
Pacifici, R, Zuccaro, P, Farre, M, Pichini, S, Di Carlo, S, Roset, PN, Hernandez Lopez, C, Ortuno, J, Segura. J, Cami, J, & de la Torre, R (2000) Immunomodulating activity of MDMA. Annals of the New York Academy of Sciences, 914: 215-224.
Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Ortuno J, Segura J, de la Torre R (1999) Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. Life Sciences, 65: L309-L316.
Peroutka, SJ, Newman, H & Harris, H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology, 1: 273-277.
Rodgers, J (2000) Cognitive performance amongst recreational users of "ecstasy." Psychopharmacology, 151: 19-24.
Rush, C, Baker, RW & Wright, K (1999) Acute physiological and behavioral effects of oral cocaine in humans. Alcohol and Drug Dependence, 55: 1-12.
Schecter, MD (1990) Functional consequences of fenfluramine neurotoxicity. Pharmacology, Biochemistry and Behavior, 37: 623-626.
Seiden LS, Kleven MS (1989) Methamphetamine and related drugs: toxicity and resulting behavioral changes in response to pharmacological probes. NIDA Research Monograph, 94: 146-160
Series, HG, Coven, PJ, & Sharp, T (1994) P-Chloroamphetamine (PCA), 3,4- methylenedioxymethamphetamine (MDMA) and d-fenfluramine pretreatment attenuates d-fenfluramine-evoked release of 5-HT in vivo. Psychopharmacology, 116; 508-513.
Siegel, RK, (1986) MDMA: Non-medical use and intoxication. Journal of Psychoactive Drugs, 18: 349-354.
Solowij N, Hall W, Lee, N (1992). Recreational MDMA use in Sydney: A profile of recreational ecstasy users and their experiences with the drug. British Journal of Addiction, 87: 1161-1172.
Stotland E (1969). Exploratory studies of empathy. In L. Berkowitz, (Ed). Advances in Experimental Social Psychology. (Vol 4) pp. 271-314. New York, NY: Academic Press.
Tancer ME, Johnson C-E (2001). The subjective effects of MDMA and mCPP in moderate MDMA users. Drug and Alcohol Dependence, 65: 97-101.
Tancer M, Johanson C-E (2003) Reinforcing, subjective and physiological effects of MDMA in humans; A comparison with d-amphetamine and mCPP. Drug and Alcohol Dependence, 72: 33-44.
Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A (2003) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology (Berl), 167: 85-96.
Verkes RJ, Gijsman HJ, Pieters MSM, Schoemaker RC, De Visser S, Kuijerps M, Pennings EJM, de Bruin D, van de Wijngaart G, Van Gerven JM, Cohen, A (2000) Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology, 153: 196-202.
Vollenweider FX, Jones RT, Baggott MJ (2001) Caveat emptor; Editors Beware. Neuropsychopharmacology, 24; 461-462.
Vollenweider FX, Gamma A, Liechti ME, Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-na�ve healthy volunteers. Neuropsychopharmacology, 19: 241-251.
Vollenweider FX, Gucker P, Sch�nb�chler R, Kamber E, Vollenweider-Scherpenhuyzen MFI, Schubiger, G, Hell, D (2000). Effects of MDMA on 5-HT uptake sites using PET and [11C]-McN5652 in humans. Data presented at 2000 conference of the German Society for Psychiatry, Psychotherapy and Neuromedicine [Deutsche Gesellschaft f�r psychiatrie, Psychotherapie und Nervenheilkunde].
Wareing M, Fisk J, Murphy, PN (2000) Working memory deficits in current and previous users of MDMA ("Ecstasy"). British Journal of Psychology, 91: 181-188.
Whitaker-Azmitia PM, Peroutka, SJ (1990) The Neuropharmacology of Serotonin. New York Academy of Sciences Press.; New York, NY.
Widmer S (1997) Listening into the heart of things: The awakening of love: On MDMA and LSD: The undesired psychotherapy. Basic Editions, Basic Editions.
Zakzanis KK, Young, DA (2001a) Memory impairment in abstinent MDMA("ecstasy") users: A longitudinal investigation. Neurology, 56: 966-969.